Shanxi C&Y Pharmaceutical Group Co Ltd (SHE:300254) — Market Cap & Net Worth
Market Cap & Net Worth: Shanxi C&Y Pharmaceutical Group Co Ltd (300254)
Shanxi C&Y Pharmaceutical Group Co Ltd (SHE:300254) has a market capitalization of $505.94 Million (CN¥3.46 Billion) as of May 3, 2026. Listed on the SHE stock exchange, this China-based company holds position #12476 globally and #3879 in its home market, demonstrating a 11.02% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shanxi C&Y Pharmaceutical Group Co Ltd's stock price CN¥13.50 by its total outstanding shares 256108563 (256.11 Million). Analyse 300254 cash flow metrics to see how efficiently the company converts income to cash.
Shanxi C&Y Pharmaceutical Group Co Ltd Market Cap History: 2015 to 2026
Shanxi C&Y Pharmaceutical Group Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.08 Billion to $505.94 Million (-5.70% CAGR).
Shanxi C&Y Pharmaceutical Group Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shanxi C&Y Pharmaceutical Group Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.39x
Shanxi C&Y Pharmaceutical Group Co Ltd's market cap is 0.39 times its annual revenue
Latest Price to Earnings (P/E) Ratio
7.77x
Shanxi C&Y Pharmaceutical Group Co Ltd's market cap is 7.77 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.08 Billion | $683.93 Million | $22.90 Million | 1.59x | 47.35x |
| 2016 | $714.31 Million | $746.08 Million | $30.15 Million | 0.96x | 23.69x |
| 2017 | $383.17 Million | $938.93 Million | $21.67 Million | 0.41x | 17.68x |
| 2018 | $242.22 Million | $1.14 Billion | $7.24 Million | 0.21x | 33.45x |
| 2019 | $303.94 Million | $1.13 Billion | $5.30 Million | 0.27x | 57.38x |
| 2020 | $258.21 Million | $848.07 Million | -$262.37 Million | 0.30x | N/A |
| 2021 | $325.67 Million | $930.37 Million | -$91.44 Million | 0.35x | N/A |
| 2022 | $253.72 Million | $829.00 Million | -$118.57 Million | 0.31x | N/A |
| 2023 | $360.90 Million | $799.31 Million | $25.20 Million | 0.45x | 14.32x |
| 2024 | $327.92 Million | $846.61 Million | $42.19 Million | 0.39x | 7.77x |
Competitor Companies of 300254 by Market Capitalization
Companies near Shanxi C&Y Pharmaceutical Group Co Ltd in the global market cap rankings as of May 3, 2026.
Key companies related to Shanxi C&Y Pharmaceutical Group Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
Shanxi C&Y Pharmaceutical Group Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Shanxi C&Y Pharmaceutical Group Co Ltd's market cap moved from $1.08 Billion to $ 505.94 Million, with a yearly change of -5.70%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥505.94 Million | +33.40% |
| 2025 | CN¥379.26 Million | +15.66% |
| 2024 | CN¥327.92 Million | -9.14% |
| 2023 | CN¥360.90 Million | +42.25% |
| 2022 | CN¥253.72 Million | -22.09% |
| 2021 | CN¥325.67 Million | +26.12% |
| 2020 | CN¥258.21 Million | -15.04% |
| 2019 | CN¥303.94 Million | +25.48% |
| 2018 | CN¥242.22 Million | -36.79% |
| 2017 | CN¥383.17 Million | -46.36% |
| 2016 | CN¥714.31 Million | -34.12% |
| 2015 | CN¥1.08 Billion | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Shanxi C&Y Pharmaceutical Group Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $505.94 Million USD |
| MoneyControl | $505.94 Million USD |
| MarketWatch | $505.94 Million USD |
| marketcap.company | $505.94 Million USD |
| Reuters | $505.94 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shanxi C&Y Pharmaceutical Group Co Ltd
ShanXi C&Y Pharmaceutical Group Co.,LTD. engages in the research, development, production, and sale of medicine and health food products. It provides anti-infective drugs, anti-allergic drugs, respiratory drugs, urinary system drugs, kidney disease drugs, children's drugs, cardiovascular and cerebrovascular drugs, anti-depressants, medicines, pharmaceutical raw materials, and intermediates, comme… Read more